Market Volatility & Investment Strategy - The market has shown resilience with a V-shaped recovery, and investors should embrace volatility as it favors long-term value buyers [1] - Despite major market averages being in the black for the year, many individual stocks, especially in the Russell 2000, are still down significantly, presenting value opportunities [4] - Stock picking is expected to outperform buying indexes, offering better sleep-at-night valuations and generous dividend yields [11] Undervalued Sectors & Stocks - The energy sector, particularly Sevitas Resources, is attractive due to being hit hard, offering a big dividend yield and low PE ratio while remaining profitable [5][6] - Pharmaceutical companies like Merc are viewed as high quality, trading at a PE around 11 with a 4% dividend yield, lower than its historical valuation [6] - Whirlpool, the appliance maker, offers a yield over 7% with a PE in the 9-10 range, anticipating support from lower interest rates later in the year [8] - Target, the discount retailer, has a low valuation relative to its history and a dividend yield pushing 5% [8][9] - UPS, the package shipping company, aligns with the theme of low valuations and generous dividend yields [9] Economic Outlook & Fed Policy - Good news rate cuts are anticipated throughout the year, although immediate cuts are unlikely due to tariff uncertainties and high inflation expectations [12][13] - Historically, stocks have performed well regardless of Fed tightening or easing, rising or falling interest rates, or high or low inflation [14] - Value stocks have historically lost only a couple percent on average during recessions, with spectacular returns of 30-40% coming out of recessions [15][16] Portfolio Valuation - The portfolio's forward earnings trade at 14 times, compared to the S&P 500's 23 times forward earnings [10] - The portfolio's overall dividend yield is 250 basis points (25%) versus 130 basis points (13%) for the S&P 500 [10]

Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. ...

Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by the ...

Core Viewpoint - Arcutis Biotherapeutics has initiated a Phase 2 open-label study for ZORYVE (roflumilast) cream 0.05% in infants with atopic dermatitis, marking a significant step in addressing unmet needs in pediatric dermatology [1][2][3] Company Overview - Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on innovations in immuno-dermatology, with a commitment to addressing urgent needs in dermatological diseases [15] Study Details - The INTEGUMENT-INFANT study will enroll approximately 35 infants aged 3 months to less than 2 years with mild to moderate atopic dermatitis, evaluating the safety and tolerability of roflumilast cream applied once daily over four weeks [3][9] - This study builds on previous successful results from the ARQ-151-105 (MUSE) study, which also evaluated roflumilast cream in infants [3] Atopic Dermatitis (AD) Insights - Atopic dermatitis is a chronic condition affecting approximately 9.6 million children in the United States, with up to 60% of cases developing symptoms within the first year of life [5][9] - The condition significantly impacts families by disrupting sleep and increasing the risk of skin infections, highlighting the need for effective treatments [2] ZORYVE Product Information - ZORYVE is the first and only branded topical therapy for atopic dermatitis, seborrheic dermatitis, and plaque psoriasis, representing a next-generation topical PDE4 inhibitor [6][7] - ZORYVE cream 0.15% is currently under FDA review for the treatment of mild to moderate atopic dermatitis in children aged 2 to 5 years, with a target action date of October 13, 2025 [8]

Core Insights - Paul Franke is a seasoned investor with 39 years of trading experience, recognized for his stock picking and macro views, having been ranked among the top investment advisors nationally during the 1990s [1] - Franke developed a stock selection system called "Victory Formation," which focuses on supply/demand imbalances indicated by specific stock price and volume movements [1] - The "Bottom Fishing Club" articles highlight deep value stocks or those showing significant upward technical momentum reversals, while "Volume Breakout Report" articles discuss positive trend changes supported by strong trading action [1] Investment Strategy - Franke recommends a diversified approach, suggesting investors hold at least 50 well-positioned stocks to achieve consistent outperformance in the stock market [1] - A stop-loss level of 10% to 20% on individual stock choices is advised to manage risk effectively [1]

Core Insights - Arcutis Biotherapeutics, Inc. is presenting five posters at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference, showcasing new data on the long-term safety and efficacy of ZORYVE cream in treating atopic dermatitis (AD) in children aged 2 to 5 [1][2] Group 1: Study Findings - The INTEGUMENT-OLE study demonstrated that ZORYVE cream 0.05% has long-term safety and durable efficacy in children aged 2 to 5 with AD, with a median duration of disease control of 238 days for those switching to a proactive twice-weekly application [2][5] - In the study, 32.7% of participants aged 6 years and older and 28.8% of participants aged 2 to 5 achieved a validated Investigator Global Assessment (vIGA-AD) score of clear or almost clear by Week 4, improving to 55.7% and 63.1% respectively by Week 52 [3][5] - Significant improvements in itch were observed, with 30.9% of participants aged 6 years and older and 41.2% of participants aged 2 to 5 achieving a clinically meaningful reduction in itch at the conclusion of the parent studies, improving to 55.3% and 60.7% respectively after up to 56 weeks of treatment [3][5] Group 2: Clinical Implications - The data highlight the critical need for effective, long-term, steroid-free treatment options for young children with AD, as chronic use of topical steroids can lead to significant adverse events [4][5] - ZORYVE cream formulations were well tolerated, with treatment-related adverse events reported in 4.7% of participants aged 6 years and older and 2.5% of participants aged 2 to 5 [4][5] - The investigational ZORYVE cream 0.05% is currently under FDA review, with a target action date of October 13, 2025, indicating potential for future market introduction [13]

Summary of Apogee Therapeutics Inc (APGE) Conference Call Company Overview - **Company**: Apogee Therapeutics Inc (APGE) - **Industry**: Pharmaceuticals and Biotechnology - **Focus**: Development of antibodies for atopic dermatitis and other inflammatory diseases Key Points and Arguments Product Development and Market Potential - Apogee is developing potentially best-in-class antibodies targeting atopic dermatitis, with a focus on long-acting IL-13 as a cornerstone asset [2][4] - The atopic dermatitis market is projected to be the largest in the inflammatory and immunology (I&I) sector, with significant unmet needs [5][11] - Upcoming phase two data is critical, with expectations to demonstrate efficacy comparable to existing treatments like Dupixent [3][7] Clinical Trial Insights - The company aims for a top-line efficacy score (EC 75) in the 45-50% range, which would position their drug as equivalent to lebrikizumab and Dupixent [8][12] - There is a strong emphasis on reducing dosing frequency from every two weeks to every three to six months, which is expected to enhance patient adherence [4][10] - Feedback from physicians indicates a high willingness to switch patients from Dupixent to Apogee's treatment if efficacy is demonstrated [9][11] Competitive Landscape - Apogee is entering a market with existing players like Dupixent, but believes there is a significant white space for new entrants [11][19] - The company is aware of potential biosimilar threats and aims to establish a strong market presence before these threats materialize [20] Regulatory Considerations - The FDA's guidance on combination therapies is vague, but Apogee plans to demonstrate that their combination therapy is superior to individual components [25][26] - The company is preparing for a factorial design study to compare their combination therapy against standard monotherapies [26][27] Financial and Market Dynamics - Estimated costs for Phase 3 trials are around $250,000 per patient, which reflects the high investment required for clinical development [30] - The company believes that the market for atopic dermatitis is large enough to support multiple successful products, even those that are not highly differentiated [18][19] Patient Adherence and Market Needs - Current adherence rates for Dupixent are around 73% in the first year, with a significant drop-off leading to cycling among treatments [35][39] - Payers are interested in long-acting therapies that can improve adherence and reduce overall healthcare costs associated with treatment cycling [40][41] Strategic Positioning - Apogee aims to position itself as a leading player in the I&I space, with a focus on developing a drug that can become the frontline treatment for atopic dermatitis [17][19] - The company is also exploring strategic partnerships or acquisitions to enhance its portfolio and market presence [71][73] Future Outlook - The upcoming data readout is expected to shift the company's risk profile from pre-data uncertainty to a more favorable position with a differentiated product offering [63][64] - There is a strong correlation between phase two and phase three success rates in atopic dermatitis, which provides confidence in the potential outcomes of their trials [67][69] Additional Important Insights - The competitive landscape is evolving, with new entrants and combination therapies being developed by other companies, such as Sanofi [48][52] - Apogee's strategy includes not only focusing on atopic dermatitis but also expanding into other indications like asthma and eosinophilic esophagitis [83][85] This summary encapsulates the critical insights from the conference call, highlighting Apogee Therapeutics' strategic direction, product development, and market positioning within the pharmaceutical industry.

Summary of Astria Therapeutics Conference Call Company Overview - **Company**: Astria Therapeutics (ATXS) - **Focus**: Development of first-choice products for patients with allergic and immunologic diseases, emphasizing competitive efficacy, safety, and low treatment burden [1] Key Product Insights - **Lead Product**: Nivenabart, a monoclonal antibody targeting plasmacallicrin, currently in Phase III trials for hereditary angioedema (HAE) [1][2] - **Efficacy Data**: Nivenabart demonstrated over 90% reduction in attack rates in proof of concept trials, with potential for dosing every six months [2][10] - **Secondary Program**: STAR310, an OX40 receptor antagonist, with Phase I data expected later in the year [2] Clinical Trial Design and Expectations - **Phase III Trial**: Includes both Q3 and Q6 month dosing regimens, initiated in February 2025, with a focus on providing options for patients and physicians [16][20] - **Enrollment**: Positive enthusiasm from patients and physicians, with expectations for top-line data in early 2027 [20] - **Regulatory Strategy**: Data from the Alpha Solar trial will support FDA filing but is not critical for the pivotal trial [12][21] Market Opportunity - **HAE Market Size**: Expected to grow to approximately $5.4 billion by 2030, driven by earlier diagnoses and increased prophylactic therapy [13][14] - **Market Positioning**: Nivenabart is positioned to capture significant market share from existing therapies, particularly TEKHZYRO, due to its competitive profile and dosing convenience [15][25] Competitive Landscape - **Atopic Dermatitis**: STAR310 targets a significant unmet need in a growing market, particularly for patients inadequately controlled by existing therapies like Dupixent [29][30] - **Differentiation Strategy**: STAR310 aims to provide efficacy without the adverse effects associated with T cell killing, which is a concern with other therapies [33][34] Financial Position and Future Catalysts - **Cash Position**: Approximately $300 million, expected to sustain operations into mid-2027 [38] - **Upcoming Catalysts**: Key data releases include long-term safety and efficacy from the Alpha Solar trial and Phase I data for STAR310, with a focus on differentiating factors [38][39] Additional Insights - **Physician Feedback**: Physicians are interested in both dosing regimens for Nivenabart, indicating a potential for flexible treatment options based on patient needs [18][19] - **Market Research**: Indications show strong interest in Nivenabart's profile, suggesting a favorable reception among physicians for switching from existing therapies [25][26] This summary encapsulates the critical points discussed during the Astria Therapeutics conference call, highlighting the company's strategic focus, product pipeline, market opportunities, and financial outlook.

Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today announced today the filing of an addendum to the 2024 Universal Registration Document (the “Addendum”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). This Addendum provides an update to the Board of Dir ...

Company to Expand Patented Wellness Approach into High-Growth Cognitive and Restorative Sleep Markets, Emphasizing Scientific Rigor and Unique Formulations SCOTTSDALE, AZ, June 03, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”), a wellness and dietary supplement company known for Sure Shot™, its patented product that rapidly lowers blood alcohol content by supporting its metabolism, today announced the initiation of research and development (R&D) for innovative ne ...